{
  "docId": "019dd923-622c-750b-8b9a-ad0811d3e80d",
  "docSlug": "dfcef8f28a20",
  "documentTitle": "Accelerate Diagnostics (AXDX)",
  "authorId": "61_White_Diamond_Research",
  "authorName": "White Diamond Research",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2019-09-16 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 33,
  "pageCount": 41,
  "prevPage": 32,
  "nextPage": 34,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide contrasts positive clinical trial data (PHENOMENON study) with negative market sentiment from a sell-side analyst survey.",
  "elementsJson": [
    "headline_text",
    "bar_chart_stacked",
    "callout_box",
    "paragraph",
    "quote_block"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-ad0811d3e80d/33",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-ad0811d3e80d",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-ad0811d3e80d.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-ad0811d3e80d#slide-33",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.78,
        "x": 0.11,
        "y": 0.53
      },
      "kind": "callout",
      "text": "Those who know the Pheno system the best do not seem to be buying.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f14c8f4-e39f-4560-b6cc-3c8c67213558",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.65,
        "x": 0.13,
        "y": 0.14
      },
      "kind": "chart",
      "text": "Percent of positive blood cultures placed on Accelerate Pheno system",
      "attrs": null,
      "subkind": "bar-stacked-100pct",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "80f4b0fd-6a45-47be-b034-ba04f14f5ada",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Percent of positive blood cultures placed on Accelerate Pheno system: 80.3%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-78b4-70ad-b3a2-322403dc45ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.78,
        "x": 0.11,
        "y": 0.44
      },
      "kind": "paragraph",
      "text": "Q2 19 numbers of installed Pheno systems in EMEA countries came out below AXDX expectations, which we believe, is consistent with a lukewarm engagement of German physicians in PHENOMENON study.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "08af0a48-3b07-423c-a1f0-7fde4c012845",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.78,
        "x": 0.11,
        "y": 0.6
      },
      "kind": "paragraph",
      "text": "In the investor update report from March 18, 2019 by Alexander Nowak, a Craig-Hallum sell-side analyst and a “believer” in AXDX’s product, ran a small size marketing survey among selected blood testing labs.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a191f80-d806-4053-a021-24bd4f17f06b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "But, we needed clarity and confidence on the annuity stream including how quickly does it ramp, are there contract minimums, pricing, etc. As a result, we concocted our current — Alexander Nowak, Craig-Hallum",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-78b4-70ad-b3a2-2d1d3bcab740",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.4,
        "x": 0.11,
        "y": 0.4
      },
      "kind": "source-note",
      "text": "Source: Slide Presentation from the ECCMID 2019",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4522dd07-9d4c-4e1b-ac68-b7f89513888a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.13,
        "y": 0.09
      },
      "kind": "title",
      "text": "PHENOMENON 6-month performance data",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b94e7e29-d27d-4da0-91d1-53cbace6f05b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "ceo-quote-contradiction",
      "slug": null,
      "matchId": "1d65e62c-59dc-46e1-9a85-22378abda7aa",
      "evidence": "Contrasts clinical performance data with market adoption failure",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 41,
      "from": 30,
      "beatId": "ca57db9c-677e-4ef8-919c-92b1690ee48e",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document implies that the solution is to be cautious of the system's limitations and avoid investment in AXDX, citing a potential decline in AXDX shares.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 35,
      "from": 31,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "c590c16d-0680-4cc5-a734-8a884e9eff8b",
      "evidence": "The document implies that the cost of inaction is the potential decline in AXDX shares and the unjustifiable premium vs its close comparator, T2 Biosystems.",
      "position": 1,
      "objective": "What is the cost of inaction regarding AXDX's Pheno system?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}